drugset / Trial / NCT02783794
BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer
Phase 2
Completed
36 enrolled
Meabco A/S
Meddoc · collabNorwegian University of Life Sciences · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine whether BP-C1 is effective in the treatment of metastatic breast cancer patients who had previously received at least three lines of chemotherapy.
Timeline
- Start
- 2012-12-24
- Primary completion
- 2014-02-28
- Completion
- 2014-02-28
Publications
- Results Larsen S, Butthongkomvong K, Manikhas A, Trishkina E, Poddubuskaya E, Matrosova M, Srimuninnimit V, Lindkaer-Jensen S. BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase. Breast Cancer (Dove Med Press). 2014 Nov 27;6:179-89. doi: 10.2147/BCTT.S71781. eCollection 2014.
- Results Erratum: BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase [Corrigendum]. Breast Cancer (Dove Med Press). 2015 Jun 29;7:163. doi: 10.2147/BCTT.S84920. eCollection 2015.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BP-C1 | Other / unclassified | 0.035 mg/kg | Intramuscular |